MOG antibodies have already been implicated in demyelinated diseases, such as ON and acute disseminated encephalomyelitis (ADEM) (Li et al., 2020; Sechi et al., 2022; Banwell et al., 2023), and have recently been shown to be potential markers for differentiating atypical ON from other ON phenotypes (De Lott et al., 2021; Petzold et al., 2022; Kraker and Chen, 2023). Here, MOG is linked to acute disseminated encephalomyelitis.